IP Library Granted Patent US 7,638,485
Granted Patent B2
US 7,638,485 · App. 11/421,918 · Granted Dec 29, 2009

Modulating apoptosis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,638,485
App. No.
11/421,918
Granted
Dec 29, 2009
Kind
B2
Abstract

The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-κB activity. The modulators may be used, for example, in the treatment of NF-κB-mediated diseases, conditions, and injuries.

Claims (13)

1. A method of protecting a mammal from ionizing radiation sufficient to cause gastrointestinal syndrome or hematopoietic syndrome comprising administering to a mammal in need thereof a composition comprising recombinant flagellin.

2. The method of claim 1 , wherein the composition is administered in combination with a radioprotectant.

3. The method of claim 2 , wherein the radioprotectant is an antioxidant.

4. The method of claim 3 , wherein the antioxidant is selected from the group consisting of amifostine and vitamin E.

5. The method of claim 2 , wherein the radioprotectant is a cytokine.

6. The method of claim 5 , wherein the cytokine is stem cell factor.

7. The method of claim 1 , wherein the composition is administered prior to, together with, or after radiation.

8. The method of claim 1 , wherein the composition is administered in combination with a growth factor.

9. The method of claim 8 , wherein the growth factor is keratinocyte growth factor.

10. The method of claim 1 , wherein the composition is administered in combination with a steroid.

11. The method of claim 10 , wherein the steroid is 5-androstenediol.

12. The method of claim 1 , wherein the composition is administered in combination with ammonium trichloro(dioxoethylene-O,O′)tellurate.

13. The method as in one of claims 1 , 2 - 6 , 7 , or 8 - 12 , wherein the mammal is a human.

Assignments (3)
ACKNOWLEDGEMENT Recorded Mar 15, 2010
From: CLEVELAND BIOLABS, INC.
To: CLEVELAND CLINIC FOUNDATION
Reel/Frame 024078/0917 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2006
From: GUDKOV, ANDREI
To: CLEVELAND BIOLABS, INC.
Reel/Frame 018526/0662 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 11, 2006
From: GUDKOV, ANDREI V.
To: THE CLEVELAND CLINIC FOUNDATION
Reel/Frame 018091/0687 →